- Trials with a EudraCT protocol (4,503)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (494)
4,503 result(s) found for: MRI.
Displaying page 3 of 226.
| EudraCT Number: 2009-015036-15 | Sponsor Protocol Number: AVIRMA | Start Date*: 2010-01-21 | |||||||||||
| Sponsor Name:Medizinische Universität Innsbruck - Universitätsklinik für Neurologie | |||||||||||||
| Full Title: Avastin / Irinotecan in patients with recurrent or progressive malignant glioma An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging techni... | |||||||||||||
| Medical condition: First or second tumour recrurrence/progression of a histological confirmed supratentorial malignant glioma WHO Grade III-IV | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002720-12 | Sponsor Protocol Number: GDX-44-016 | Start Date*: 2023-03-20 | |||||||||||
| Sponsor Name:Guerbet | |||||||||||||
| Full Title: Performance of Elucirem® (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas | |||||||||||||
| Medical condition: Naive or recurrent primary glial tumor | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001869-32 | Sponsor Protocol Number: 24042019 | Start Date*: 2020-01-29 |
| Sponsor Name:Radboudumc | ||
| Full Title: Nano-MRI to visualize pancreatic inflammation in individuals with recent-onset type 1 diabetes | ||
| Medical condition: Type 1 Diabetes | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-003461-41 | Sponsor Protocol Number: HP4.3 | Start Date*: 2007-11-13 |
| Sponsor Name:Deutsche Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler | ||
| Full Title: Cardiac imaging under dobutamine stress for early assessment of right ventricular function in patients with tetralogy of Fallot and pulmonary regurgitation | ||
| Medical condition: Fallot tetralogy late after repair with marked pulmonary valve incompetence | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004310-18 | Sponsor Protocol Number: SPL-01-001 | Start Date*: 2019-10-07 | |||||||||||
| Sponsor Name:Saving Patients' Lives Medical B.V. | |||||||||||||
| Full Title: A confirmatory, prospective, open-label, single-arm, reader-blinded multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unen... | |||||||||||||
| Medical condition: newly-diagnosed prostate cancer (PCA) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002329-27 | Sponsor Protocol Number: ETLAS-2 | Start Date*: 2020-12-10 | ||||||||||||||||
| Sponsor Name:Herlev Gentofte Hospital | ||||||||||||||||||
| Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial. | ||||||||||||||||||
| Medical condition: Cerebral small vessel disease and stroke. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-000827-11 | Sponsor Protocol Number: T50/2021 | Start Date*: 2022-09-02 |
| Sponsor Name:Turku University Hospital | ||
| Full Title: Clinical use of USPIO contrast media in the assessment of pelvic lymph node metastasis in rectal cancer. | ||
| Medical condition: Pelvic lymph node metastasis in rectal cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-005555-27 | Sponsor Protocol Number: ESR-14-10473 | Start Date*: 2017-09-12 |
| Sponsor Name:University Hospital Basel | ||
| Full Title: Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A randomised multi-centre phase II trial comparing Ticagrelor versus Clopidogrel with outcome assessment on MRI (PR... | ||
| Medical condition: Carotid artery stenting (CAS) is treatment for atherosclerotic carotid stenosis. The main adverse events are thromboembolic brain infarcts during the procedure. Ticagrelor, a novel reversible inhib... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-002130-20 | Sponsor Protocol Number: 1.4 | Start Date*: 2020-02-07 | ||||||||||||||||
| Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust | ||||||||||||||||||
| Full Title: Research on Efficacy of Teriparatide use in the Return of recruits to Normal duty. | ||||||||||||||||||
| Medical condition: Healthy individuals with stress fractures. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-000690-78 | Sponsor Protocol Number: 19773 | Start Date*: 2018-10-29 | |||||||||||
| Sponsor Name:Bayer AG | |||||||||||||
| Full Title: LowEr Administered Dose with highEr Relaxivity: Gadovist vs Dotarem | |||||||||||||
| Medical condition: Contrast enhancement in magnetic resonance imaging (MRI) for central nervous system (CNS), magnetic resonance (MR) angiography, liver, kidney and other body regions | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-005886-19 | Sponsor Protocol Number: HGKKRWPHD2 | Start Date*: 2012-07-31 | ||||||||||||||||||||||||||
| Sponsor Name:Gastroenterology MIDT | ||||||||||||||||||||||||||||
| Full Title: Correlation between intestinal blOod flow assessed by magNetic resonance imaging and ulTRASound Techniques (CONTRAST) | ||||||||||||||||||||||||||||
| Medical condition: Crohns Disease with active disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-003386-22 | Sponsor Protocol Number: PRX302-2-07 | Start Date*: 2015-01-19 |
| Sponsor Name:Sophiris Bio Corp | ||
| Full Title: A Single Centre, Open Label, Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Signific... | ||
| Medical condition: Prostate cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-006414-19 | Sponsor Protocol Number: RD 2007-114 | Start Date*: 2009-04-27 | |||||||||||
| Sponsor Name:East and North Hertfordhsire NHS Trust | |||||||||||||
| Full Title: Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-α in patients with advanced renal cell carcinoma. | |||||||||||||
| Medical condition: Previously untreated metastatic (stage IV) or locally advanced (inoperable stage III), renal cell carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002672-12 | Sponsor Protocol Number: 73807 | Start Date*: 2020-12-11 |
| Sponsor Name:Erasmus Medical Center | ||
| Full Title: Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects | ||
| Medical condition: Frontotemporal dementia (FTD), including symptomatic patients and presymptomatic individuals with genetic mutations predisposing to FTD at a later stage in life. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004519-43 | Sponsor Protocol Number: NN18344 | Start Date*: 2005-01-12 |
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||
| Full Title: Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis | ||
| Medical condition: Relapsing Multiple Sclerosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) GB (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) SK (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-004456-42 | Sponsor Protocol Number: P2021/Anesth/MIDEXMRI | Start Date*: 2022-06-21 |
| Sponsor Name:Hôpital Universitaire Des Enfants Reine Fabiola | ||
| Full Title: Prospective, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial comparing the safety and efficacy of intranasal dexmedetomidine to oral midazolam as premedication for... | ||
| Medical condition: pre-school pediatric population undergoing magnetic resonance imaging | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-004847-61 | Sponsor Protocol Number: 008717QM | Start Date*: 2013-01-16 | |||||||||||
| Sponsor Name:Queen Mary University of London | |||||||||||||
| Full Title: A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhan... | |||||||||||||
| Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001879-20 | Sponsor Protocol Number: 38RC18.085 | Start Date*: 2018-07-30 | |||||||||||
| Sponsor Name:Grenoble Alps University Hospital | |||||||||||||
| Full Title: Radiotherapy of multiple brain metastases using AGuIX® gadolinium-chelated polysiloxane based nanoparticles: a prospective randomized phase II clinical trial. | |||||||||||||
| Medical condition: Patients with brain metastases, from a histologically confirmed solid tumor, eligible for WBRT | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-024477-39 | Sponsor Protocol Number: 105MS302 | Start Date*: 2011-05-06 | |||||||||||
| Sponsor Name:Biogen Idec Limited | |||||||||||||
| Full Title: A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis | |||||||||||||
| Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) BE (Completed) DE (Completed) ES (Completed) BG (Completed) EE (Completed) GB (Completed) GR (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-006338-32 | Sponsor Protocol Number: WA21493 | Start Date*: 2008-05-06 | |||||||||||
| Sponsor Name:Hoffman La Roche Ltd | |||||||||||||
| Full Title: Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... | |||||||||||||
| Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) CZ (Completed) SK (Completed) DK (Completed) BE (Completed) NL (Completed) FI (Completed) BG (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.